IKT
$1.96
Inhibikase Therapeutics, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, wh...
Recent News
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
The stock market has been treading water so far this year, with the S&P 500 up roughly 1% while the Nasdaq has slipped 1.5%. Tech stocks have struggled to regain last year’s momentum as investors reassess the durability of AI-driven spending, the margin impact of massive capital expenditures, and whether growth rates can justify the premium multiples many companies still command. That skepticism toward richly valued mega-cap tech has pushed investors to look elsewhere for returns, and biotech ha
Sands Capital Opens $10 Million ServiceTitan Position
ServiceTitan offers cloud software for field service management, generating recurring revenue from a broad base of service professionals.
Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company
Key Insights The considerable ownership by individual investors in Inhibikase Therapeutics indicates that they...
Inhibikase Therapeutics Insiders Placed Bullish Bets Worth US$2.70m
In the last year, multiple insiders have substantially increased their holdings of Inhibikase Therapeutics, Inc...
Hedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term losses
Key Insights Institutions' substantial holdings in Inhibikase Therapeutics implies that they have significant influence...